logo-loader
viewIXICO PLC

IXICO PLC secures significant new contracts with two new clients

IXICO PLC's (LON:IXI) John Hall came into Proactive London to discuss two significant new contracts they've agreed with new biopharmaceutical clients.

The first contract, to support an early phase study into Huntington’s Disease (HD), is worth around £2mln and will be delivered over seven years.

The other's for a Phase 3 study for another rare neurological disease.

Quick facts: IXICO PLC

Price: 70.5 GBX

AIM:IXI
Market: AIM
Market Cap: £33.07 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of IXICO PLC named herein, including the promotion by the Company of IXICO PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Proactive meets IXICO's new chief business officer Lammert...

Lammert Albers sits down with Proactive London's Andrew Scott soon after his appointment as IXICO PLC’s (LON:IXI) chief business officer. With expertise of the Alzheimer's disease trials market he says he'll be responsible for executing the company's global business development strategy in...

1 week, 2 days ago

2 min read